Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-O
2024-510782-42-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of alpelisib and olaparib in High-Grade Serous Ovarian Cancer (HGSOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival (PFS). Started Oct 2021; status: completed.
02
Drugs
alpelisibolaparib
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-510782-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510782-42-00.